...
【24h】

Lead content of calcium supplements.

机译:钙补充剂的铅含量。

获取原文
获取原文并翻译 | 示例
           

摘要

CONTEXT: Substantial quantities of lead have been reported in some over-the-counter calcium supplement preparations, including not only bone-meal and dolomite, but also over-the-counter natural and refined calcium carbonate formulations. Examination of this issue is warranted given recent increases in physician recommendations for calcium supplements for prevention and treatment of osteoporosis. OBJECTIVES: To determine the lead content of calcium supplements and to quantify the lead exposure from popular brands of calcium in dosages used for childhood recommended daily allowance, osteoporosis, and phosphate binding in dialysis patients. DESIGN AND SETTING: Analysis of lead content in 21 formulations of nonprescription calcium carbonate (including 7 natural [ie, oyster shell] and 14 refined), 1 brand of prescription-only calcium acetate, and 1 noncalcium synthetic phosphate binder conducted in March 2000. MAIN OUTCOME MEASURES: Lead content, assayed using electrothermal atomic absorption, expressed as micrograms of lead per 800 mg/d of elemental calcium, per 1500 mg/d of calcium, and for a range of dosages for patients with renal failure. Six microg/d of lead was considered the absolute dietary limit, with no more than 1 microg/d being the goal for supplements. RESULTS: Four of 7 natural products had measurable lead content, amounting to approximately 1 microg/d for 800 mg/d of calcium, between 1 and 2 microg/d for 1500 mg/d of calcium, and up to 10 microg/d for renal dosages. Four of the 14 refined products had similar lead content, including up to 3 microg/d of lead in osteoporosis calcium dosages and up to 20 microg/d in high renal dosages. No lead was detected in the calcium acetate or polymer products. Lead was present even in some brand name products from major pharmaceutical companies not of natural oyster shell derivation. CONCLUSIONS: Despite increasingly stringent limits of lead exposure, many calcium supplement formulations contain lead and thereby may pose an easily avoidable public health concern. JAMA. 2000;284:1425-1429.
机译:上下文:在一些非处方钙补充剂制剂中已报道了大量的铅,不仅包括骨粉和白云石,还包括非处方天然和精制碳酸钙制剂。鉴于最近医师对预防和治疗骨质疏松症的钙补充剂的建议有所增加,因此有必要对该问题进行检查。目的:确定钙补充剂中的铅含量,并量化流行品牌钙的铅暴露量,这些剂量可用于透析患者的儿童建议每日津贴,骨质疏松和磷酸盐结合。设计与地点:2000年3月进行了21种非处方碳酸钙(包括7种天然[即牡蛎壳]和14种精制),1种仅处方处方的乙酸钙和1种非钙合成磷酸盐粘合剂中铅含量的分析。主要观察指标:铅含量,使用电热原子吸收法测定,表示为每800 mg / d元素钙,每1500 mg / d钙微克铅,以及肾衰竭患者的一系列剂量。铅的每日摄入量限制为六微克/天,补充品的目标是不超过一微克/天。结果:7种天然产品中有4种具有可测量的铅含量,钙800毫克/天的含量约为1微克/天,钙1500毫克/天的含量约为1至2微克/天,而钙的最高含量为10微克/天。肾脏剂量。 14种精制产品中有4种具有相似的铅含量,包括骨质疏松钙剂量中的铅含量高达3微克/天,高肾脏剂量中的铅含量高达20微克/天。在乙酸钙或聚合物产品中未检测到铅。甚至在主要制药公司的某些品牌产品中也存在铅,这些产品不是天然牡蛎壳衍生的。结论:尽管铅暴露的限制越来越严格,但许多钙补充剂配方中都含有铅,因此可能引起容易避免的公共卫生问题。贾玛2000; 284:1425-1429。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号